S
Samar Issa
Researcher at University of California, San Francisco
Publications - 4
Citations - 408
Samar Issa is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Rituximab & Primary central nervous system lymphoma. The author has an hindex of 3, co-authored 4 publications receiving 369 citations.
Papers
More filters
Journal ArticleDOI
Phase I Study of Intraventricular Administration of Rituximab in Patients With Recurrent CNS and Intraocular Lymphoma
James L. Rubenstein,Jane Fridlyand,Lauren E. Abrey,Arthur Shen,Jon Karch,Endi Wang,Samar Issa,Lloyd E. Damon,Michael D. Prados,Michael T. McDermott,Joan M. O'Brien,Christopher M. Haqq,Marc A. Shuman +12 more
TL;DR: In this article, the authors conducted a phase I dose-escalation study of intrathecal rituximab monotherapy in patients with recurrent CNS non-Hodgkin's lymphoma (NHL).
Journal ArticleDOI
Immunochemotherapy with Intensive Consolidation for Primary CNS Lymphoma: A Pilot Study and Prognostic Assessment by Diffusion-Weighted MRI
Matthew J. Wieduwilt,Francisco Valles,Samar Issa,Caroline Behler,Jimmy Hwang,Michael W. McDermott,Patrick A. Treseler,Joan M. O'Brien,Marc A. Shuman,Soonmee Cha,Lloyd E. Damon,James L. Rubenstein +11 more
TL;DR: Tumor ADCmin derived from DW-MRI provided better prognostic information for PCNSL patients treated with the MTR-EA regimen than established clinical risk scores and was significantly associated with shorter progression-free and overall survival.
Journal ArticleDOI
Treatment of Primary CNS Lymphoma with Induction High-Dose Methotrexate, Temozolomide, Rituximab Followed by Consolidation Cytarabine/Etoposide: A Pilot Study with Biomarker Analysis.
Samar Issa,Arthur Shen,Jon Karch,Cigall Kadoch,Marc A. Shuman,Lloyd E. Damon,James L. Rubenstein +6 more
TL;DR: Combination MTR followed by intensive consolidation appears to be well tolerated in PCNSL and PFS appears at least similar to regimens that contain whole brain irradiation.
Journal ArticleDOI
Treatment of primary CNS lymphoma with induction high-dose methotrexate, temozolomide, rituximab followed by consolidation cytarabine/etoposide: A pilot study with biomarker analysis
Samar Issa,Jimmy Hwang,Jon Karch,Jane Fridlyand,Michael D. Prados,Tracy T. Batchelor,Kenneth Aldape,Christopher M. Haqq,Lloyd E. Damon,James L. Rubenstein +9 more
TL;DR: Pilot analysis to determine the safety and efficacy of intensive methotrexate-based induction therapy followed by high-dose consolidation with elimination of whole brain irradiation and analysis of molecular markers in PCNSL which predict sensitivity to chemotherapy and outcome.